/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing in the discovery, development, and commercialization of innovative medicines and vaccines across diverse therapeutic areas. With a strong late-stage pipeline and strategic partnerships, Pfizer maintains a robust presence in both established and emerging healthcare markets.
The New York-based company is slated to announce its fiscal Q2 2025 results before the market opens on Tuesday, Aug. 5. Ahead of the event, analysts predict Pfizer to report an adjusted EPS of $0.57, down 5% from $0.60 in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, PFE exceeded the consensus adjusted EPS estimate by 43.8%.
For fiscal 2025, analysts expect the drugmaker to report adjusted EPS of $3.06, a decline of 1.6% from $3.11 in fiscal 2024. Nevertheless, adjusted EPS is anticipated to grow nearly 1% year-over-year to $3.09 in fiscal 2026.
Shares of Pfizer have dropped 8.2% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 11.9% rise and the Health Care Select Sector SPDR Fund's (XLV) 7.1% decrease over the same period.
Shares of Pfizer rose 3.2% on Apr. 29 after the company reported Q1 2025 adjusted EPS of $0.92, beating the consensus estimate and rising 12% year-over-year. Despite an 8% revenue decline to $13.7 billion, investors reacted positively to strong performance from key products like Comirnaty, Vyndaqel family, and Padcev. Additionally, Pfizer reaffirmed its full-year 2025 guidance, projecting revenue between $61 billion - $64 billion and EPS of $2.80 - $3, signaling confidence in its pipeline and cost control.
Analysts' consensus rating on Pfizer stock is moderately optimistic, with a "Moderate Buy" rating overall. Among 22 analysts covering the stock, six recommend a "Strong Buy,” one has a "Moderate Buy" rating, 14 give a "Hold" rating, and one suggests a "Strong Sell.” This configuration is slightly less bullish than three months ago, with seven analysts suggesting a "Strong Buy."
As of writing, the stock is trading below the average analyst price target of $27.71.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
